Michael Feldman

1955-2005 Weizmann Institute of Science, Rehovot, Israel 
cancer research, cellular immunology, developmental biology
"Michael Feldman"

(1926 - 2005)

BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ruella M, Klichinsky M, Kenderian SS, et al. (2017) Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discovery
Posey AD, Schwab RD, Boesteanu AC, et al. (2016) Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. Immunity. 44: 1444-1454
Bhoj VG, Arhontoulis D, Wertheim G, et al. (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood
Wang E, Wang LC, Tsai CY, et al. (2015) Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research. 3: 815-26
Motz GT, Santoro SP, Wang LP, et al. (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature Medicine. 20: 607-15
Tsygankova OM, Ma C, Tang W, et al. (2010) Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Molecular and Cellular Biology. 30: 3262-74
Domchek SM, Recio A, Mick R, et al. (2007) Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance. Cancer Research. 67: 10546-55
Carmon L, El-Shami KM, Paz A, et al. (2000) Novel breast-tumor-associated MUC1-derived peptides: Characterization in D(b-)/- x β2 microglobulin (β2m) null mice transgenic for a chimeric HLA- A2.1/D(b)-β2 microglobulin single chain International Journal of Cancer. 85: 391-397
El-Shami KM, Tirosh B, Popovic D, et al. (2000) Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide International Journal of Cancer. 85: 236-242
Tirosh B, el-Shami K, Vaisman N, et al. (1999) Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination. Immunology Letters. 70: 21-8
See more...